Edition:
India

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

57.04USD
15 Dec 2017
Change (% chg)

$-1.19 (-2.04%)
Prev Close
$58.23
Open
$58.21
Day's High
$59.11
Day's Low
$56.79
Volume
563,204
Avg. Vol
523,834
52-wk High
$88.80
52-wk Low
$42.63

Select another date:

Tue, Nov 21 2017

BRIEF-Dexcom announces development agreement with Lilly

* Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

BRIEF-‍Janus Henderson reports 10.2 pct passive stake in Dexcom

* ‍Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing​ Source text: (http://bit.ly/2ybb4kH) Further company coverage:

BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes

* ‍Fitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes​

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-DexCom ‍publishes new study on people with type 2 diabetes

* DexCom-‍ published new study showing type 2 diabetes people on a multiple daily injection insulin therapy benefit from use of continuous glucose monitoring​ Source text for Eikon: Further company coverage:

BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO

* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million

Select another date: